Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta2-agonists and bronchial hyperresponsiveness.

Clive P Page1, Domenico Spina

  • 1Sackler Institute of Pulmonary Pharmacology, School of Biomedical and Health Sciences, King's College London, United Kingdom. clive.page@kcl.ac.uk

Clinical Reviews in Allergy & Immunology
|November 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

The Platelet/Megakaryocyte Axis is Necessary for Allergic Sensitisation and Inflammatory Responses to House Dust Mite in the Lung.

Lung·2026
Same author

The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung.

Lung·2026
Same author

Platelet-specific P2Y<sub>1</sub> receptor deficient mice have suppressed pulmonary leukocyte recruitment in response to lipopolysaccharide.

Respiratory research·2026
Same author

Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.

Respiratory research·2025
Same journal

β-blocker Therapy in Cholinergic Urticaria, Adrenergic Urticaria and the Aquagenic Continuum Beta-Blocker Therapy in Chronic Inducible Urticaria.

Clinical reviews in allergy & immunology·2026
Same journal

Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.

Clinical reviews in allergy & immunology·2026
Same journal

Neuropsychological Factors in Vitiligo: Mechanisms and Clinical Application.

Clinical reviews in allergy & immunology·2026
Same journal

Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases.

Clinical reviews in allergy & immunology·2026
Same journal

Differentiating Acute-onset Autoimmune Hepatitis From Drug-Induced Autoimmune-like Hepatitis: A Multicenter Study and Score Development.

Clinical reviews in allergy & immunology·2026
Same journal

Mapping Neuro Behcet's Disease Across North Africa: a Systematic Review and Meta Analysis.

Clinical reviews in allergy & immunology·2026
See all related articles

Bronchial hyperresponsiveness (BHR), a hallmark of asthma, can be worsened by environmental factors and certain medications. Paradoxically, regular use of asthma symptom treatments like beta2-agonists may increase BHR, potentially contributing to asthma severity.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Bronchial hyperresponsiveness (BHR) is a key characteristic of the asthma phenotype.
  • Asthma patients exhibit exaggerated responses to various physiological and chemical stimuli.
  • Factors like allergens, pollutants, viruses, NSAIDs, and beta-blockers can increase BHR.

Purpose of the Study:

  • To review current understanding of BHR in asthma.
  • To examine mechanisms behind increased BHR.
  • To discuss the paradoxical effect of beta2-agonists on BHR.

Main Methods:

  • Literature review of BHR mechanisms.
  • Analysis of factors influencing BHR.
  • Discussion of beta2-agonist effects on asthma morbidity.

Main Results:

Related Experiment Videos

  • BHR is a defining feature of asthma, influenced by environmental and drug exposures.
  • Regular beta2-agonist treatment may paradoxically increase BHR.
  • Increased BHR is linked to rising asthma morbidity and mortality.

Conclusions:

  • Understanding BHR mechanisms is crucial for asthma management.
  • The paradoxical effect of beta2-agonists warrants further investigation.
  • Further research is needed to mitigate BHR and improve asthma outcomes.